Clearside Biomedical Inc
NASDAQ:CLSD
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.9274
2.02
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CLSD stock under the Base Case scenario is 0.63 USD. Compared to the current market price of 1.08 USD, Clearside Biomedical Inc is Overvalued by 41%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Clearside Biomedical Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CLSD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Clearside Biomedical Inc
Balance Sheet Decomposition
Clearside Biomedical Inc
Current Assets | 25.1m |
Cash & Short-Term Investments | 23.6m |
Receivables | 788k |
Other Current Assets | 734k |
Non-Current Assets | 4m |
PP&E | 4m |
Other Non-Current Assets | 30k |
Current Liabilities | 5.6m |
Accounts Payable | 2.4m |
Accrued Liabilities | 3.2m |
Non-Current Liabilities | 58.4m |
Other Non-Current Liabilities | 58.4m |
Earnings Waterfall
Clearside Biomedical Inc
Revenue
|
7.7m
USD
|
Cost of Revenue
|
-230k
USD
|
Gross Profit
|
7.5m
USD
|
Operating Expenses
|
-32.1m
USD
|
Operating Income
|
-24.6m
USD
|
Other Expenses
|
-7.2m
USD
|
Net Income
|
-31.9m
USD
|
Free Cash Flow Analysis
Clearside Biomedical Inc
USD | |
Free Cash Flow | USD |
CLSD Profitability Score
Profitability Due Diligence
Clearside Biomedical Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Clearside Biomedical Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
CLSD Solvency Score
Solvency Due Diligence
Clearside Biomedical Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Clearside Biomedical Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CLSD Price Targets Summary
Clearside Biomedical Inc
According to Wall Street analysts, the average 1-year price target for CLSD is 6.12 USD with a low forecast of 5.05 USD and a high forecast of 8.4 USD.
Dividends
Current shareholder yield for CLSD is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
CLSD Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Clearside Biomedical, Inc. is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. The company is headquartered in Alpharetta, Georgia and currently employs 34 full-time employees. The company went IPO on 2016-06-02. The firm is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. The company is focused on developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector, and it also partners with companies developing other ophthalmic therapeutics to be administered using its SCS injection platform. Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. Its pipeline includes CLS-AX, CLS-301 and Gene Therapy.
Contact
IPO
Employees
Officers
The intrinsic value of one CLSD stock under the Base Case scenario is 0.63 USD.
Compared to the current market price of 1.08 USD, Clearside Biomedical Inc is Overvalued by 41%.